This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Juventas Cell Therapy Ltd.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Na An - Innovator in Chimeric Antigen Receptor Technology
Introduction
Na An is a prominent inventor based in Tianjin, China. He has made significant contributions to the field of immunotherapy, particularly through his work on chimeric antigen receptors (CARs). His innovative approach aims to enhance the effectiveness of immune cells in targeting cancer cells.
Latest Patents
Na An holds a patent for a CD19-targeted chimeric antigen receptor and its applications. This patent includes a chimeric antigen receptor comprising an amino acid sequence shown in SEQ ID NO. 1. It also covers a nucleic acid encoding the chimeric antigen receptor, a vector comprising the nucleic acid, and an immune effector cell that incorporates the chimeric antigen receptor. Furthermore, the patent outlines methods for preparing the immune effector cell, compositions that include the immune effector cell, and the use of the chimeric antigen receptor in therapeutic applications. He has 1 patent to his name.
Career Highlights
Na An is currently associated with Juventas Cell Therapy Ltd., where he continues to advance his research in cell therapy and immunology. His work is pivotal in developing new treatments for cancer, leveraging the power of the immune system.
Collaborations
Na An collaborates with notable colleagues, including Jianxiang Wang and Min Wang, who contribute to his research endeavors. Their combined expertise enhances the potential for groundbreaking advancements in the field.
Conclusion
Na An's innovative work in chimeric antigen receptor technology positions him as a key figure in the fight against cancer. His contributions are paving the way for new therapeutic strategies that harness the immune system's capabilities.